Refine by
Eye Care Articles & Analysis
32 news found
In general, cosmetics and personal care products can be classified into seven categories, i.e., oral care, skin care, sun care, hair care, decorative cosmetics, body care, and perfumes. “Currently, dozens of hand sanitizers, skincare, body care, and hair ...
WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO). Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye ...
(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. ...
With a 26.8% prevalence of diabetes for people over the age of 65, there are 14.3 million seniors alone who are at risk of developing visual loss or blindness. Diabetic eye diseases are treatable, and blindness can be prevented for most patients with early detection and treatment. However, in some areas as low as 15% of people with diabetes get the recommended annual diabetic ...
This complementary alliance will support iSTAR Medical’s development and commercial efforts for MINIject®, as well as provide an opportunity to expand AbbVie’s eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and stent offerings. ...
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
(Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced publication in Clinical Ophthalmology of its 12-month outcomes in the GEMINI study, including results from a Hispanic population subset. ...
Jan Darius Unterlauft at Inselspital, Bern WAVRE, Belgium — 10 May 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. ...
SAN DIEGO–(BUSINESS WIRE) (March 15th, 2022) –Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors. ...
Commercial rollout continues following European approval in 2021 WAVRE, Belgium — 12 January 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced initial positive progress of MINIject™ in its US STAR-V trial. ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). ...
“We’re collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients. With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.” Ocugen’s modifier gene therapy platform aims to target nuclear hormone ...
Szaronos has been instrumental in leading teams and bringing innovations to market to address unmet needs throughout eye care. Mr. Szaronos joined TearLab's executive team as Chief Commercial Officer in 2020 after the company was acquired by investment firm Accelmed Partners. ...
BySOFIE
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. ...
CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete ...
“There are over 8 million people with diabetes in Bangladesh, many of whom don’t have access to the care they need, such as routine diabetic eye exams,” said Michael Abramoff, MD, PhD, Founder and Executive Chairman of Digital Diagnostics. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. ...
Early detection can help empower patients with the necessary information to make changes to their lifestyle, and ensure plans are in place for their long-term care. Using the eye’s retina as a window to brain health “The eye is a natural window to the brain through the retina, as it’s an anatomical extension of the ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ocular hypertension. ...